US EditionASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
- On May 31, 2025, Novoxel Inc. And GPOphtho revealed a partnership aimed at broadening the availability of Novoxel’s Tixel device range throughout the United States.
- The partnership seeks to equip eyecare providers across the country with innovative solutions for dry eye management and cosmetic treatments utilizing FDA-approved technology.
- Tixel i, designed specifically to treat Meibomian Gland Dysfunction, offers a fast, targeted, non-invasive solution that treats both upper and lower eyelids in two minutes.
- Cynthia Matossian, MD, CEO of GPOphtho, highlighted that Tixel i offers a quick treatment duration of just two minutes for both eyes and effectively addresses both the upper and lower eyelids to enhance therapeutic outcomes safely.
- The agreement provides GPOphtho's network discounted pricing and value-added packages, enabling eyecare professionals to integrate functional and cosmetic procedures that create new revenue streams and enhance patient satisfaction.
Insights by Ground AI
Does this summary seem wrong?
78 Articles
78 Articles
All
Left
8
Center
21
Right
8
Bennington Banner+76 Reposted by 76 other sources
Novoxel Inc. and GPOphtho Finalize Strategic Agreement to Deliver Breakthrough Dry Eye Treatments and Aesthetic Procedures to Eyecare Physicians Nationwide
KNOXVILLE, Tenn., May 31, 2025 /PRNewswire/ -- Novoxel Inc. and GPOphtho announce their agreement to expand access to Novoxel's innovative Tixel® device family across the United States. This collaboration aims to deliver breakthrough dry eye treatments and aesthetic procedures to…
Coverage Details
Total News Sources78
Leaning Left8Leaning Right8Center21Last UpdatedBias Distribution57% Center
Bias Distribution
- 57% of the sources are Center
57% Center
L 22%
C 57%
R 22%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
